Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL

Leukaemia Section

Short Communication

t(3;12)(q26;p13) ETV6/MECOM / t(3;12)(q26;p13) ETV6/EVI1

Etienne De Braekeleer, Nathalie Douet-Guilbert, Marc De Braekeleer

Cytogenetics Laboratory, Faculty of Medicine, University of Brest, France (EDB, NDG, MDB)

Published in Atlas Database: April 2014

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0312.html DOI: 10.4267/2042/54377

This article is an update of : Desangles F. t(3;12)(q26;p13). Atlas Genet Cytogenet Oncol Haematol 1997;1(1):21.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Short communication on t(3;12)(q26;p13) ETV6/MECOM, with data on clinics, and the genes implicated.

Identity

Note

Only a few cases were shown to involve a ETV6/MECOM fusion by FISH or RT-PCR. In other cases, only MECOM or ETV6 was shown to be rearranged by FISH. Over-expression of MECOM/EVI1 was found in other cases. Finally, no cytogenetic or molecular analysis was performed in a few cases.



t(3;12)(q26;p13) G-banding - Courtesy Jean-Luc Lai and Alain Vanderhaegen.Clinics and pathology

Disease

Myeloid lineage: MDS in transformation, ANLL, BC-CML

Phenotype/cell stem origin

Multilineage involvement; MDS--> M0, M2, M4,

M7.

Epidemiology

46 cases described so far; sex ratio: 29M/16F (1 unknown); age: 2.5-87 yrs (med: 49 yrs), unknown age for 10 cases.

Cytology

Dysplasia of megakaryocytes, multilineage involvement.

Prognosis

See survival curve above.

Cytogenetics

Cytogenetics molecular

Heterogeneity of the EVI1 breakpoints, as evidenced by the Cytocell Aquarius EVI1 Breakapart probe.

The EVI1 Breakapart probe contains three probes: a probe labeled in Aqua of 562 kb in size centromeric to the EVI1 gene, a probe labeled in Spectrum Green of 181 kb covering EVI1 and its flanking regions and a probe labeled in Spectrum Orange of 124 kb telomeric of the EVI1 gene (telomeric of MYNN and covering LRRC34).

Additional anomalies

Sole anomaly in 22 cases.

Additional anomalies: t(9;22)(q34;q11) in 5 cases, -7/del(7q) in 11 cases, del(5q) in 2 cases, others in 6 cases.





Survival curve (21 patients, Mean: 12 mths, Median: 10 mths).

Genes involved and proteins

MECOM

Location 3q26

Note Alias EVI1

DNA/RNA

MECOM is a "complex entity" made of two genes, EVI1 and MDS1.

EVI1 has 16 exons, of which 14 are coding, the start ATG codons being in exon 3.

MDS1 has 4 exons, exon 4 being located in the vicinity of exon 1 of EVI1.

Splicing of the second exon of MDS1 to the second exon of EVI1 leads to a MDS1-EVI1 mRNA.

Protein

EVI1 contains two domains of seven and three zinc finger motifs separated by a repression domain and an acidic domain at its C-terminus.

ETV6

Location 12p13

Note

The ETV6 gene encodes a transcription factor frequently rearranged in myeloid and lymphoid leukemias.

DNA/RNA

The ETV6 gene spans a region of less than 250 kb at band 12p13.1 and consists of 8 exons. There are two start codons, one (exon 1a starting at codon 1) located at the beginning of the gene and another alternative (exon 1b starting at codon 43) upstream of exon 3.

Protein

The ETV6 protein (452 amino acids) contains two major domains, the HLH (helix-loop-helix) and ETS domains. The HLH domain, also referred to as the pointed or sterile alpha motif domain, is encoded by exons 3 and 4 and functions as a homooligodimerization domain. The ETS domain, encoded by exons 6 through 8, is responsible for sequence specific DNA-binding and protein-protein interaction.

Result of the chromosomal anomaly

Hybrid gene

Description

Two mechanisms for generating the fusion gene, depending upon the involvement of the MDS1 gene.

Transcript

1) In-frame transcript consisting of the first two exons of ETV6 fused to MDS1 sequences, which in turn is fused to the second exon of the EVI1 gene.



Schematic diagram of the ETV6, EVI1, MDS1, MDS1-EVI1, ETV6-EVI1 and ETV6-MDS1-EVI1 proteins.

2) Out-of-frame fusion by direct fusion between exon 2 of ETV6 and exon 2 of EVI1, but keeping the open reading frame of EVI1 intact.

Fusion protein

Description

ETV6 contributes no known functional domain to the predicted chimeric protein but functional domains of EVI1 are retained.

Oncogenesis

The oncogenic potential of the translocation could be the result of the ETV6 promoter driving the transcription of EVI1. Because the ETV6 promoter is active in hematopoietic cells, this would result in inappropriate expression of the transcription factor EVI1.

References

Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994 Apr 22;77(2):307-16

Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995 Oct;91(2):490-501

Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1642-7

Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B, Ayraud N, Marynen P. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in

myelodysplastic syndromes. Blood. 1996 Jul 15;88(2):682-9

Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997 Dec;11(12):2022-31

Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res. 1997 Feb 15;57(4):564-9

Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia. 1997 Mar;11(3):352-8

van de Loosdrecht AA, Kok K, de Vries B, van der Veen AY, van den Berg E, Esselink MT, Marynen P, Vellenga E, van Imhoff GW. Breakpoint analysis by fluorescence in situ hybridization in myelodysplastic syndromes with t(3;12)(q26;p13) and expression of EVI1. Leukemia. 2000 Oct;14(10):1857-8

Nakamura Y, Nakazato H, Sato Y, Furusawa S, Mitani K. Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). Am J Hematol. 2002 Jan;69(1):80-2

Voutsadakis IA, Maillard N. Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature. Am J Hematol. 2003 Feb;72(2):135-7

Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeijer A, Speleman F. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer. 2006 Apr;45(4):349-56

Bobadilla D, Enriquez EL, Alvarez G, Gaytan P, Smith D, Slovak ML. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br J Haematol. 2007 Mar;136(6):806-13 Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene. 2007 Jul 15;396(2):346-57

Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet. 2011 Jul;204(7):392-7

Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger

M, Kern W, Haferlach T. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012 Apr;51(4):328-37

This article should be referenced as such:

De Braekeleer E, Douet-Guilbert N, De Braekeleer M. t(3;12)(q26;p13) ETV6/MECOM. Atlas Genet Cytogenet Oncol Haematol. 2014; 18(12):950-953.